Eltrombopag (Promacta) 25mg/50mg Tablets | US Originator TPO-R Agonist | GLT

Generic Information: Promacta (United States)

Generic name: eltrombopag olamine. Brand name: Promacta. Manufacturer: Novartis. Origin: United States (originator). Strength: 25 mg and 50 mg film-coated tablets, 30 tablets per bottle. Class: thrombopoietin receptor agonist (TPO-RA), a non-peptide small molecule that binds the transmembrane domain of the c-Mpl receptor.

Promacta is the United States brand of the originator eltrombopag, first approved by the FDA in 2008 as the first oral TPO receptor agonist for immune thrombocytopenia. The identical molecule is sold as Revolade in the European Union and China. Both are manufactured by Novartis, which has held global rights to eltrombopag since 2015.

What Is Promacta Used For?

Promacta raises platelet counts in two core indications. First, chronic immune thrombocytopenia (ITP) in adults and children aged 1 year and older who have not responded adequately to corticosteroids, immunoglobulins or splenectomy. Second, severe aplastic anemia (SAA) in patients with an insufficient response to immunosuppressive therapy. In the United States it is also approved for thrombocytopenia associated with chronic hepatitis C to allow interferon-based treatment.

How Does Promacta Work?

Eltrombopag binds directly to the transmembrane region of the thrombopoietin receptor (c-Mpl) on megakaryocytes, triggering JAK2/STAT signalling that drives megakaryocyte proliferation, differentiation and platelet release. Because it binds a site distinct from where endogenous thrombopoietin binds, Promacta works additively with the body's own TPO rather than competing with it. It is the reference oral therapy that spared patients the daily injections of earlier recombinant TPO products.

Indications

• Chronic immune thrombocytopenia (ITP) in adults and children ≥1 year with inadequate response to corticosteroids, IVIG or splenectomy
• Severe aplastic anemia (SAA) with inadequate response to immunosuppressive therapy
• Thrombocytopenia associated with chronic hepatitis C, to enable interferon-based therapy

Dosage

For ITP, adults and children 6 years and older usually start at 50 mg once daily, while children 1–5 years start at 25 mg once daily; the dose is titrated to maintain platelets at or above 50 × 10⁹/L, not exceeding 75 mg daily. For SAA, the typical starting dose is 50 mg once daily for adults. East Asian patients and those with hepatic impairment start at a lower dose.

Promacta must be taken on an empty stomach — one hour before or two hours after a meal — and separated by at least two hours from dairy products and supplements containing calcium, iron, magnesium, aluminium, selenium or zinc, which sharply reduce absorption.

Side Effects

The most common adverse reactions are headache, nausea, diarrhoea, fatigue, muscle aches and upper respiratory symptoms. More serious risks require monitoring: hepatotoxicity (liver enzymes are checked before and periodically during treatment), thromboembolic events, and cataract formation. Regular platelet counts and liver function tests are essential while on therapy.

Storage

Store Promacta tablets at room temperature (20–25°C), in a dry place away from light and moisture. Keep the bottle tightly closed and out of reach of children.

Why Choose Promacta from GLT?

Promacta is the single most clinically established oral TPO-RA in the world, backed by the largest evidence base in the class across ITP and SAA. GLT sources this US originator directly through regulated channels and ships worldwide with full documentation. For buyers who want the reference FDA-approved brand — or who are already established on Promacta and need continuity of supply — GLT offers a reliable cross-border route with Certificate of Analysis, Certificate of Pharmaceutical Product and batch traceability on every order.

How to Order

To request a quotation for US-sourced Promacta in 25 mg or 50 mg (30-tablet bottles), contact GLT on WhatsApp +86 15234153837 or email [email protected]. Both institutional and individual buyers are supported, with ambient shipping for these oral tablets.

FAQ

Is Promacta the same as Revolade? Yes. Promacta and Revolade are the identical Novartis originator eltrombopag under different regional brand names — Promacta in the United States, Revolade in the EU and China.

What strengths does Promacta come in? Promacta is available as 25 mg and 50 mg film-coated tablets, supplied 30 tablets per bottle.

Who makes Promacta? Novartis, the Swiss innovator that has held global rights to eltrombopag since 2015.

How is Promacta taken? Once daily on an empty stomach, one hour before or two hours after food, and two hours apart from dairy and mineral supplements.

Can I buy Promacta from GLT? Yes. GLT arranges US-sourced originator Promacta for international buyers with complete export documentation.